Related references
Note: Only part of the references are listed.Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
Laurence Catley et al.
BLOOD (2006)
Mitochondria as the target of the pro-apoptotic protein Bax
Ernine Er et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2006)
Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824
Shaowen Wang et al.
CELL CYCLE (2006)
JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells
Bong-Jo Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Histone deacetylase inhibitors: Multifunctional anticancer agents
Tao Liu et al.
CANCER TREATMENT REVIEWS (2006)
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275
LY Eyüpoglu et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells
ST Nawrocki et al.
CANCER RESEARCH (2006)
Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells
Takeo Fujita et al.
ANTI-CANCER DRUGS (2006)
Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib
K Sutheesophon et al.
ACTA HAEMATOLOGICA (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Acetylation and deacetylation of non-histone proteins
MA Glozak et al.
GENE (2005)
Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas
M Entin-Meer et al.
MOLECULAR CANCER THERAPEUTICS (2005)
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006
CR Yu et al.
ONCOGENE (2005)
Synergistic apoptosis induction by proteasome and histone deacetylase inhibitors is dependent on protein synthesis
HCA Drexler et al.
APOPTOSIS (2005)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo
IY Eyüpoglu et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme
C Giannini et al.
NEURO-ONCOLOGY (2005)
Drug Insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid
WK Kelly et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)
D Yin et al.
ONCOGENE (2005)
Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge
D Soni et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2005)
Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis
HY Cohen et al.
MOLECULAR CELL (2004)
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis
CE Denlinger et al.
ANNALS OF THORACIC SURGERY (2004)
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells
M Adachi et al.
CLINICAL CANCER RESEARCH (2004)
Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils
SJ Gardai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells
G Dewson et al.
ONCOGENE (2003)
The proteasome: a novel target for cancer chemotherapy
JB Almond et al.
LEUKEMIA (2002)
The permeability transition pore signals apoptosis by directing Bax translocation and multimerization
F De Giorgi et al.
FASEB JOURNAL (2002)
Expression of bcl-2, bax and bcl-xl in human gliomas:: A re-appraisal
S Martin et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Share Paper
